Why CEL-SCI (CVM) Shares Are Trading Higher - CEL-SCI (AMEX:CVM)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
CEL-SCI Corp (CVM) Receives FDA Go-Ahead for Confirmatory Study of Multikine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biotech CEL-SCI gets FDA go-ahead to conduct investigational cancer immunotherapy study
thedailyrecord.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailyrecord.com Daily Mail and Mail on Sunday newspapers.
[December 29, 2020]
VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into EuropeÂ
TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. and Israel, with over 200 patients enrolled to date.
âVB-111 is our proprietary anti-cancer gene therapy product candidate that has shown overall survival benefit across multiple tumor types,â said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. âWe are pleased to expand the OVAL potential registration study of VB-111 in patients with late stage ovarian cancer to E